Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.

Thevenon J, Bourredjem A, Faivre L, Cardot-Bauters C, Calender A, Murat A, Giraud S, Niccoli P, Odou MF, Borson-Chazot F, Barlier A, Lombard-Bohas C, Clauser E, Tabarin A, Parfait B, Chabre O, Castermans E, Beckers A, Ruszniewski P, Le Bras M, Delemer B, Bouchard P, Guilhem I, Rohmer V, Goichot B, Caron P, Baudin E, Chanson P, Groussin L, Du Boullay H, Weryha G, Lecomte P, Penfornis A, Bihan H, Archambeaud F, Kerlan V, Duron F, Kuhn JM, Vergès B, Rodier M, Renard M, Sadoul JL, Binquet C, Goudet P.

Hum Mol Genet. 2013 May 15;22(10):1940-8. doi: 10.1093/hmg/ddt039. Epub 2013 Jan 31.

2.

Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.

Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A, Bonithon-Kopp C.

World J Surg. 2010 Feb;34(2):249-55. doi: 10.1007/s00268-009-0290-1.

PMID:
19949948
3.

Unraveling the intrafamilial correlations and heritability of tumor types in MEN1: a Groupe d'étude des Tumeurs Endocrines study.

Thevenon J, Bourredjem A, Faivre L, Cardot-Bauters C, Calender A, Le Bras M, Giraud S, Niccoli P, Odou MF, Borson-Chazot F, Barlier A, Lombard-Bohas C, Clauser E, Tabarin A, Pasmant E, Chabre O, Castermans E, Ruszniewski P, Bertherat J, Delemer B, Christin-Maitre S, Beckers A, Guilhem I, Rohmer V, Goichot B, Caron P, Baudin E, Chanson P, Groussin L, Du Boullay H, Weryha G, Lecomte P, Schillo F, Bihan H, Archambeaud F, Kerlan V, Bourcigaux N, Kuhn JM, Vergès B, Rodier M, Renard M, Sadoul JL, Binquet C, Goudet P.

Eur J Endocrinol. 2015 Dec;173(6):819-26. doi: 10.1530/EJE-15-0691. Epub 2015 Sep 21.

4.

Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein.

Wautot V, Vercherat C, Lespinasse J, Chambe B, Lenoir GM, Zhang CX, Porchet N, Cordier M, Béroud C, Calender A.

Hum Mutat. 2002 Jul;20(1):35-47.

PMID:
12112656
5.

Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.

Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2387-91. doi: 10.1210/jc.2013-4432. Epub 2014 Sep 11.

PMID:
25210877
6.

Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.

Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Vergès B, Chabre O, Calender A; Groupe d'études des Tumeurs Endocrines.

Am J Surg Pathol. 2008 Apr;32(4):534-43. doi: 10.1097/PAS.0b013e31815ade45.

PMID:
18300794
7.

Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms.

Shimazu S, Nagamura Y, Yaguchi H, Ohkura N, Tsukada T.

Cancer Sci. 2011 Nov;102(11):2097-102. doi: 10.1111/j.1349-7006.2011.02055.x. Epub 2011 Sep 1.

8.

Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines.

Goudet P, Bonithon-Kopp C, Murat A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Cadiot G, Beckers A, Guilhem I, Chabre O, Caron P, Du Boullay H, Verges B, Cardot-Bauters C.

Eur J Endocrinol. 2011 Jul;165(1):97-105. doi: 10.1530/EJE-10-0950. Epub 2011 May 6.

9.

MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases.

Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S, Albarello L, Doglioni C, Schott C, Capelli P, Chilosi M, Boninsegna L, Becker KF, Falconi M, Scarpa A.

Endocr Relat Cancer. 2010 Aug 16;17(3):771-83. doi: 10.1677/ERC-10-0028. Print 2010 Sep.

10.

Multiple endocrine neoplasia type 1.

Agarwal SK.

Front Horm Res. 2013;41:1-15. doi: 10.1159/000345666. Epub 2013 Mar 19. Review.

PMID:
23652667
11.

Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1).

Gaztambide S, Vazquez F, Castaño L.

Minerva Endocrinol. 2013 Mar;38(1):17-28. Review.

PMID:
23435440
12.

The gene for multiple endocrine neoplasia type 1: recent findings.

Marx SJ, Agarwal SK, Heppner C, Kim YS, Kester MB, Goldsmith PK, Skarulis MC, Spiegel AM, Burns AL, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Emmert-Buck MR, Guru SC, Manickam P, Crabtree JS, Collins FS, Chandrasekharappa SC.

Bone. 1999 Jul;25(1):119-22. Review.

PMID:
10423035
13.

Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines).

Goudet P, Murat A, Cardot-Bauters C, Emy P, Baudin E, du Boullay Choplin H, Chapuis Y, Kraimps JL, Sadoul JL, Tabarin A, Vergès B, Carnaille B, Niccoli-Sire P, Costa A, Calender A; GTE network (Groupe des Tumeurs Endocrines).

World J Surg. 2009 Jun;33(6):1197-207. doi: 10.1007/s00268-009-9980-y.

PMID:
19294466
14.

Menin molecular interactions: insights into normal functions and tumorigenesis.

Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji Y, Mateo C, Libutti SK, Oliver B, Chandrasekharappa SC, Burns AL, Collins FS, Spiegel AM, Marx SJ.

Horm Metab Res. 2005 Jun;37(6):369-74. Review.

PMID:
16001329
15.

Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database.

Gatta-Cherifi B, Chabre O, Murat A, Niccoli P, Cardot-Bauters C, Rohmer V, Young J, Delemer B, Du Boullay H, Verger MF, Kuhn JM, Sadoul JL, Ruszniewski P, Beckers A, Monsaingeon M, Baudin E, Goudet P, Tabarin A.

Eur J Endocrinol. 2012 Feb;166(2):269-79. doi: 10.1530/EJE-11-0679. Epub 2011 Nov 14.

16.

MEN1 gene and its mutations: basic and clinical implications.

Tsukada T, Nagamura Y, Ohkura N.

Cancer Sci. 2009 Feb;100(2):209-15. doi: 10.1111/j.1349-7006.2008.01034.x. Review.

17.

Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype.

Perakakis N, Flohr F, Kayser G, Thomusch O, Parsons L, Billmann F, von Dobschuetz E, Rondot S, Seufert J, Laubner K.

Hormones (Athens). 2016 Jan-Mar;15(1):113-7. doi: 10.14310/horm.2002.1626.

18.

Impaired transforming growth factor-β (TGF-β) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1).

Canaff L, Vanbellinghen JF, Kaji H, Goltzman D, Hendy GN.

J Biol Chem. 2012 Mar 9;287(11):8584-97. doi: 10.1074/jbc.M112.341958. Epub 2012 Jan 24.

19.

Characteristics of the Danish families with multiple endocrine neoplasia type 1.

Jäger AC, Friis-Hansen L, Hansen TV, Eskildsen PC, Sølling K, Knigge U, Hansen CP, Andersen PH, Brixen K, Feldt-Rasmussen U, Kroustrup JP, Mollerup CL, Rehfeld JF, Blichert-Toft M, Nielsen FC.

Mol Cell Endocrinol. 2006 Apr 25;249(1-2):123-32. Epub 2006 Mar 23.

PMID:
16563611
20.

Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation.

Dreijerink KM, Höppener JW, Timmers HM, Lips CJ.

Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):562-70. Review.

PMID:
17024155

Supplemental Content

Support Center